Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Gastroenterol Hepatol ; 19(11): 2230-2240.e1, 2021 11.
Article in English | MEDLINE | ID: mdl-33493695

ABSTRACT

Food allergy is an aberrant immunological response to food antigen, which can result in potentially life-threatening reactions. It is often challenging to differentiate food allergy from other adverse reactions to food because their presentations can be indistinguishable. The purpose of this article is to give an overview of the classification, evaluation, and management of adverse food reactions, key differentiating features of food allergy, roles and limitations of various food allergy testing, and promising areas of emerging research. Case studies are used to highlight some of the clinical pearls in diagnosing and managing food-related diseases.


Subject(s)
Food Hypersensitivity , Diagnosis, Differential , Food Hypersensitivity/diagnosis , Food Hypersensitivity/therapy , Humans
2.
Ann N Y Acad Sci ; 1481(1): 154-169, 2020 12.
Article in English | MEDLINE | ID: mdl-32428279

ABSTRACT

Gastroesophageal reflux disease (GERD) is a common condition characterized by troublesome symptoms or esophageal mucosal lesions attributed to excessive esophageal acid exposure. Various pathophysiological mechanisms account for GERD, including impaired esophageal peristalsis and anatomical or physiological defects at the esophagogastric junction (EGJ). Endoscopy identifies GERD complications and detects potential alternative diagnoses. However, if symptoms persist despite proton pump inhibitor therapy, functional esophageal tests are useful to characterize reflux burden and define the symptom association profile. Ambulatory pH or pH-impedance monitoring measures the 24-h acid exposure time, which remains the most reproducible reflux metric and predicts response to antireflux therapy. Apart from identifying peristaltic dysfunction, esophageal high-resolution manometry defines the morphology and contractile vigor (EGJ-CI) of the EGJ. Novel metrics obtained from pH-impedance monitoring include the postreflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance, which augment the diagnostic value of pH-impedance testing. Mucosal impedance can also be recorded using a probe inserted through a gastroscope, or a novel balloon catheter with arrays of impedance electrodes inserted following sedated endoscopy. The latest developments in functional esophageal tests define the GERD phenotype based on pathogenesis, reflux exposure, structural or motility disorders, and symptom burden, facilitating appropriate treatment.


Subject(s)
Catheter Ablation , Electric Impedance , Esophageal pH Monitoring , Esophagoscopy , Gastroesophageal Reflux , Proton Pump Inhibitors/therapeutic use , Esophageal Mucosa/physiopathology , Esophagogastric Junction/physiopathology , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/physiopathology , Gastroesophageal Reflux/therapy , Humans
3.
Med Clin North Am ; 103(1): 71-87, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30466677

ABSTRACT

Gastroparesis is an increasing concern and options remain limited. Diagnosis hinges on recognition of delayed gastric emptying in the absence of mechanical obstruction. Nontransit studies evaluating gastric motility serve a complementary role and may help guide therapy. Treatment consists of a combination of lifestyle and dietary medication, medications (antiemetics, prokinetics, neuromodulators, and accommodation-enhancers), alternative and complementary therapy, endoscopic therapy (pyloric-directed therapy, temporary stimulation, jejunostomy, or venting gastrostomy) and surgical therapy (pyloroplasty, gastric electrical stimulation, gastrectomy). Treatment can be tailored to the individual needs and symptoms of the affected patient.


Subject(s)
Gastroparesis/therapy , Complementary Therapies/methods , Diet/methods , Electric Stimulation Therapy/methods , Endoscopy, Gastrointestinal/methods , Female , Gastrectomy/methods , Gastrointestinal Agents/therapeutic use , Gastroparesis/diagnosis , Humans , Life Style , Male , Stomach/physiopathology
6.
Dig Endosc ; 27(4): 479-485, 2015 May.
Article in English | MEDLINE | ID: mdl-25394296

ABSTRACT

BACKGROUND AND AIM: SpyGlass® cholangiopancreatoscopy system has shown early success in aiding diagnosis and management of pancreaticobiliary diseases. We aimed to assess the technical success, clinical success, diagnostic yield, therapeutic yield, and safety of the SpyGlass® system at a single institution. METHODS: A retrospective, single-center review of consecutive patients who underwent endoscopic retrograde cholangiopancreatography with SpyGlass® between January 2008 and August 2013 for a variety of indications. Technical success was defined as the procedure being completed as planned. Clinical success was defined as a successful outcome using diagnostic, clinical, laboratory, or imaging evidence. RESULTS: SpyGlass® cholangioscopy was carried out in 88 patients (49 females, mean age 56.9 ± 15.5 years). Indications were diagnostic in 67 and therapeutic in 21. Overall, technical success was seen in 87.5% and clinical success in 77.3%. Thirty-nine patients with indeterminate biliary stricture had technical and clinical success rates of 92.3% and 74.4%, respectively. In this subgroup, malignancy was ultimately diagnosed in 13 with 12 patients diagnosed by SpyGlass® and confirmed by surgical specimens in 12/12 cases; positive predictive value 100%). In the 23 remaining patients with indeterminate biliary strictures, one was later found to have malignancy (negative predictive value 95.8%) after 1 year of follow up. In the 13 therapeutic cases of stone removal, technical and clinical success was seen in 77.0% for both. Overall, adverse events were seen in 15.9%. CONCLUSIONS: SpyGlass® demonstrated acceptable technical and clinical success rates in both diagnostic and therapeutic procedures. In particular, it allows for an accurate rate of diagnosis of indeterminate biliary strictures.


Subject(s)
Bile Duct Diseases/diagnosis , Bile Duct Diseases/surgery , Cholangiopancreatography, Endoscopic Retrograde/instrumentation , Natural Orifice Endoscopic Surgery/instrumentation , Adult , Aged , Aged, 80 and over , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Equipment Design , Female , Humans , Image-Guided Biopsy/adverse effects , Image-Guided Biopsy/instrumentation , Male , Middle Aged , Natural Orifice Endoscopic Surgery/adverse effects , Outcome Assessment, Health Care , Predictive Value of Tests , Retrospective Studies , Young Adult
7.
Cell Metab ; 13(2): 222-32, 2011 Feb 02.
Article in English | MEDLINE | ID: mdl-21284989

ABSTRACT

The identity of higher-order neurons and circuits playing an associative role to control feeding is unknown. We injected pseudorabies virus, a retrograde tracer, into masseter muscle, salivary gland, and tongue of BAC-transgenic mice expressing GFP in specific neural populations and identified several CNS regions that project multisynaptically to the periphery. MCH and orexin neurons were identified in the lateral hypothalamus, and Nurr1 and Cnr1 in the amygdala and insular/rhinal cortices. Cholera toxin ß tracing showed that insular Nurr1(+) and Cnr1(+) neurons project to the amygdala or lateral hypothalamus, respectively. Finally, we show that cortical Cnr1(+) neurons show increased Cnr1 mRNA and c-Fos expression after fasting, consistent with a possible role for Cnr1(+) neurons in feeding. Overall, these studies define a general approach for identifying specific molecular markers for neurons in complex neural circuits. These markers now provide a means for functional studies of specific neuronal populations in feeding or other complex behaviors.


Subject(s)
Eating , Neurons/metabolism , Animals , Cholera Toxin/pharmacology , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Herpesvirus 1, Suid/genetics , Mice , Mice, Transgenic , Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism , Receptor, Cannabinoid, CB1/genetics , Receptor, Cannabinoid, CB1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL